Local treatment of a bone graft by soaking in zoledronic acid inhibits bone resorption and bone formation. A bone chamber study in rats

BMC Musculoskeletal Disorders

Magnus Tägil²  Hanna Isaksson¹  Ola Belfrage² 

[1] Division of Solid Mechanics, Lund University, Lund, Sweden;Department of Orthopedics, Clinical Sciences, Lund University and Skåne University Hospital, Lund, S-221 85, Sweden

关键词: Bone remodelling;    Local treatment;    Allograft;    Bisphosphonates;    Zoledronic acid;   

Others  :  1134404
DOI  :  10.1186/1471-2474-13-240

 received in 2011-12-27, accepted in 2012-11-26,  发布年份 2012

【 摘 要 】

Background

Bone grafts are frequently used in orthopaedic surgery. Graft remodelling is advantageous but can occur too quickly, and premature bone resorption might lead to decreased mechanical integrity of the graft. Bisphosphonates delay osteoclastic bone resorption but may also impair formation of new bone. We hypothesize that these effects are dose dependent. In the present study we evaluate different ways of applying bisphosphonates locally to the graft in a bone chamber model, and compare that with systemic treatment.

Methods

Cancellous bone grafts were placed in titanium chambers and implanted in the tibia of 50 male rats, randomly divided into five groups. The first group served as negative control and the grafts were rinsed in saline before implantation. In the second and third groups, the grafts were soaked in a zoledronic acid solution (0.5 mg/ml) for 5 seconds and 10 minutes respectively before being rinsed in saline. In the fourth group, 8 μL of zoledronic acid solution (0.5 mg/ml) was pipetted onto the freeze-dried grafts without rinsing. The fifth group served as positive control and the rats were given zoledronic acid (0.1 mg/kg) systemically as a single injection two weeks after surgery. The grafts were harvested at 6 weeks and analysed with histomorphometry, evaluating the ingrowth distance of new bone into the graft as an equivalent to the anabolic osteoblast effect and the amount (bone volume/total volume; BV/TV) of remaining bone in the remodelled graft as equivalent to the catabolic osteoclast effect.

Results

In all chambers, almost the entire graft had been revascularized but only partly remodelled at harvest. The ingrowth distance of new bone into the graft was lower in grafts soaked in zoledronic acid for 10 minutes compared to control (p = 0.007). In all groups receiving zoledronic acid, the BV/TV was higher compared to control.

Conclusions

This study found a strong inhibitory effect on bone resorption by bisphosphonates but also a limited inhibition of the ingrowth of new bone. Local treatment at surgery resulted in stronger inhibition of both resorption and bone formation compared to systemic treatment.

【 授权许可】

   
2012 Belfrage et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Leopold SS, Jacobs JJ, Rosenberg AG: Cancellous allograft in revision total hip arthroplasty. A clinical review. Clin Orthop Relat Res 2000, 86:97.
• [2]Linder L: Cancellous impaction grafting in the human femur: histological and radiographic observations in 6 autopsy femurs and 8 biopsies. Acta Orthop Scand 2000, 71:543-552.
• [3]Marsell R, Einhorn TA: The biology of fracture healing. Injury 2011, 42:551-555.
• [4]Toms AD, Barker RL, Jones RS, Kuiper JH: Impaction bone-grafting in revision joint replacement surgery. J Bone Joint Surg Am 2004, 86-A:2050-2060.
• [5]Tagil M, Astrand J, Westman L, Aspenberg P: Alendronate prevents collapse in mechanically loaded osteochondral grafts: a bone chamber study in rats. Acta Orthop Scand 2004, 75:756-761.
• [6]Belfrage O, Flivik G, Sundberg M, Kesteris U, Tagil M: Local treatment of cancellous bone grafts with BMP-7 and zoledronate increases both the bone formation rate and bone density: a bone chamber study in rats. Acta Orthop 2011, 82:228-233.
• [7]Kesteris U, Aspenberg P: Rinsing morcellised bone grafts with bisphosphonate solution prevents their resorption. A prospective randomised double-blinded study. J Bone Joint Surg Brit Vol 2006, 88:993-996.
• [8]Russell RG, Watts NB, Ebetino FH, Rogers MJ: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759.
• [9]Greiner SH, Wildemann B, Back DA, Alidoust M, Schwabe P, Haas NP, Schmidmaier G: Local application of zoledronic acid incorporated in a poly(D, L-lactide)-coated implant accelerates fracture healing in rats. Acta Orthop 2008, 79:717-725.
• [10]Aspenberg P, Astrand J: Bone allografts pretreated with a bisphosphonate are not resorbed. Acta Orthop Scand 2002, 73:20-23.
• [11]Baas J, Elmengaard B, Jensen TB, Jakobsen T, Andersen NT, Soballe K: The effect of pretreating morselized allograft bone with rhBMP-2 and/or pamidronate on the fixation of porous Ti and HA-coated implants. Biomaterials 2008, 29:2915-2922.
• [12]Jakobsen T, Baas J, Bechtold JE, Elmengaard B, Soballe K: The effect of soaking allograft in bisphosphonate: a pilot dose–response study. Clin Orthop Relat Res 2010, 468:867-874.
• [13]Agholme F, Aspenberg P: Experimental results of combining bisphosphonates with allograft in a rat model. J Bone Joint Surg Br 2009, 91:670-675.
• [14]Jakobsen SS, Danscher G, Stoltenberg M, Larsen A, Bruun JM, Mygind T, Kemp K, Soballe K: Cobalt-chromium-molybdenum alloy causes metal accumulation and metallothionein up-regulation in rat liver and kidney. Basic Clin Pharmacol Toxicol 2007, 101:441-446.
• [15]Jeppsson C, Astrand J, Tagil M, Aspenberg P: A combination of bisphosphonate and BMP additives in impacted bone allografts. Acta Orthop Scand 2003, 74:483-489.
• [16]Seo SW, Cho SK, Storer SK, Lee FY: Zoledronate reduces unwanted bone resorption in intercalary bone allografts. Int Orthop 2010, 34:599-603.
• [17]Tagil M, Aspenberg P, Astrand J: Systemic zoledronate precoating of a bone graft reduces bone resorption during remodeling. Acta Orthop 2006, 77:23-26.
• [18]Merz WA, Schenk RK: A quantitative histological study on bone formation in human cancellous bone. Acta Anat (Basel) 1970, 76:1-15.
• [19]Orriss IR, Key ML, Colston KW, Arnett TR: Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem 2009, 106:109-118.
• [20]Idris AI, Rojas J, Greig IR, Van AMP, Apos T, Hof RJ, Ralston SH: Aminobisphosphonates Cause Osteoblast Apoptosis and Inhibit Bone Nodule Formation In Vitro. Calcif Tissue Int 2008, 82(3):191-201.
• [21]Greiner S, Kadow-Romacker A, Lubberstedt M, Schmidmaier G, Wildemann B: The effect of zoledronic acid incorporated in a poly(D, L-lactide) implant coating on osteoblasts in vitro. J Biomed Mater Res A 2007, 80:769-775.
• [22]Aft R: Bisphosphonates in breast cancer: clinical activity and implications of preclinical data. Clin Adv Hematol Oncol 2011, 9:194-205.
• [23]Bukowski JF, Dascher CC, Das H: Alternative bisphosphonate targets and mechanisms of action. Biochem Biophys Res Commun 2005, 328:746-750.
• [24]Schindeler A, Little DG: Bisphosphonate action: revelations and deceptions from in vitro studies. J Pharm Sci 2007, 96:1872-1878.
• [25]Board TN, Rooney P, Kay PR: Strain imparted during impaction grafting may contribute to bony incorporation: AN IN VITRO STUDY OF THE RELEASE OF BMP-7 FROM ALLOGRAFT. J Bone Joint Surg Br 2008, 90-B:821-824.